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Abstract
Information on the safety of medication use during pregnancy and breastfeeding is scarce, yet use of medication among 
pregnant and breastfeeding women is widespread. The pREGnant, the Dutch Pregnancy Drug Register, was set up to obtain 
insight into medication use among pregnant and breastfeeding women and potential effects on maternal and fetal/infant 
health. The systematically documented, good quality data on medication use during pregnancy and lactation in pREGnant 
will be used in signal detection, epidemiologic studies and counseling of healthcare providers and patients. The register has 
a prospective cohort design. The population is derived from pregnant women throughout the Netherlands. Data collection 
started in April 2014 and enrollment of women is continuous and is characterized by a relative high proportion of women 
born in the Netherlands with a high education compared with the general Dutch pregnant population. Data on current 
pregnancy, obstetric history, maternal lifestyle, health and medication use, delivery, and infant health are collected through 
web-based questionnaires completed by the participating women (three times during pregnancy and three times during the 
infant’s first year of life). If permission is given, the self-reported data can be complemented with information retrieved from 
Perined, the perinatal registry of the Netherlands, and from obstetric and medical records, and/or pharmacy records. Here, 
we provide detailed information on the design of the pREGnant, the Dutch Pregnancy Drug Register, as well as descriptive 
information on characteristics of the participants so far. Currently, steps are being taken to implement the register on a large 
scale in the Netherlands.
Key Points 
The ultimate aim of the pREGnant, the Dutch Pregnancy 
Drug Register, is to provide practical recommendations 
for the pharmaceutical care of pregnant and postpartum 
women.
To obtain more knowledge on medication use among 
pregnant and breastfeeding women and potential effects 
on maternal and fetal/infant health, it is important to 
have well documented, high-quality data on exposures, 
outcomes, and covariables.
1 Introduction
When a medicine is marketed, information about its use dur-
ing pregnancy and lactation is sparse and mostly limited to 
animal studies. Pre-marketing clinical trials do not include 
pregnant women, except when the product is specifically 
intended to be used in pregnancy [1]. Therefore, information 
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on pregnancy and offspring outcomes as a result of medica-
tion use can only be acquired post-marketing when medi-
cation is used by pregnant women in daily practice [2–4]. 
Despite the lack of safety information, medication use 
among pregnant and breastfeeding women is widespread 
with prevalence estimates ranging between 40 and 96% 
of women taking at least one prescribed medication dur-
ing pregnancy [5–9]. The lack of knowledge may hamper 
optimal treatment of pregnant and breastfeeding women as 
it might affect prescribing behavior of healthcare provid-
ers (HCPs) or adherence to the treatment [10, 11]. Certain 
maternal illnesses, however, pose a risk for maternal or fetal 
health without proper pharmacological treatment [12–18]. 
Due to unwarranted concerns, women might not try to get 
pregnant or pregnancies may be terminated unnecessarily, 
whereas fetal development in other pregnancies may be put 
at risk because of exposure to medication with unknown 
teratogenic effects [11, 19]. In addition, neonates may not 
benefit from breastfeeding due to non-initiation or cessation 
when the mother needs medication [20, 21].
Several established approaches are currently in place to 
increase the knowledge on the safety profile of medication 
use during pregnancy and lactation. While some of these 
are more appropriate to detect potential signals of safety 
concerns, others might be more suitable to perform expo-
sure–outcome association studies [22]. Spontaneous reports 
of cases in pharmacovigilance databases are a valuable 
source when generating hypotheses and identifying highly 
teratogenic medications. Marketing authorization holders 
(MAHs) are obliged to monitor all pregnancies that are 
exposed to their product. They may also be requested to 
set up a pregnancy registry. Although these registries are 
of value for signal generation, their contribution to signal 
confirmation is limited due to, for instance, a large amount 
of missing data, high attrition rates, and the lack of appropri-
ate controls [23]. Pharmacoepidemiologic studies to assess 
exposure–outcome associations need to make use of large 
datasets. Big data approaches using linkage of data readily 
available in healthcare databases are often population-based 
and have large sample sizes. As these data are not collected 
for research purposes, however, the quality of the data might 
be limited and important variables may be lacking (e.g., life-
style factors, detailed information on exposure) [24–28]. The 
strength of non-selective case–control approaches, such as in 
the National Birth Defects Prevention Study (NBDPS) and 
the European surveillance of congenital anomalies (EURO-
CAT), is the high statistical power that enables the detec-
tion of teratogenic medication, even if the outcome is rare. 
However, information bias and in particular recall bias are a 
major threat to the validity of case–control studies [29–32].
In the Netherlands, no central database existed that docu-
mented relevant, good quality information to address a vari-
ety of questions regarding medication use during pregnancy 
and breastfeeding on a large scale in a systematic and contin-
uous way. Therefore, we developed the pREGnant, the Dutch 
Pregnancy Drug Register. The ultimate aim of pREGnant is 
to obtain more insight into medication use among pregnant 
and breastfeeding women and safety aspects concerning 
maternal and fetal/infant health. In the present article, we 
provide detailed information on the design of pREGnant, 
as well as descriptive information on characteristics of the 
participants enrolled from April 1, 2014 until March 31, 
2018, the effectiveness of several recruitment methods, and 
the follow-up rates. Also, the strengths and limitations of its 
design and future perspectives are discussed.
2  Design of pREGnant
2.1  Target Population
The target population of the pREGnant, the Dutch Preg-
nancy Drug Register, is pregnant women throughout the 
Netherlands (approximately 170,000 births/year) [33]. The 
inclusion criteria are (i) proficiency in the Dutch language 
and (ii) having access to the internet. The latter was true for 
over 99% of Dutch women between 18 and 45 years in 2017 
[34]. The only exclusion criterion is being under 18 years 
of age. We aim to enroll women in pREGnant as early in 
pregnancy as possible, although women can enroll at any 
time throughout the entire pregnancy. The use of medica-
tion at enrollment is no prerequisite, since women might use 
medication later in pregnancy or during the breastfeeding 
period. If not, they could be included in a reference group 
in future studies.
2.2  Recruitment Methods
Pregnant women are recruited in several ways. Both mid-
wifes and gynecologists are asked to invite pregnant women 
at their first contact or first prenatal care visit, generally 
around gestational weeks 8–10. These HCPs, as well as 
others (e.g., pharmacists, neurologists), can send preg-
nant women an automatically generated digital invitation 
through their account on the pREGnant website (https ://
www.pregn ant.nl). This personalized invitation is signed by 
the HCP and provides information on participation, includ-
ing information that is needed for a woman to access the 
online informed consent form directly. Alternatively, the 
HCP hands out an information leaflet about the register, in 
which women are invited to participate. In that case, the 
woman can sign up on the pREGnant website. The infor-
mation on the website is sufficient to inform the woman on 
what to expect when participating. In case of any remaining 
questions, she can get in touch with the pREGnant team by 
e-mail. HCPs who contact the Dutch Teratology Information 
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Service (TIS) for telephone counseling are asked to inform 
their patients about participation in pREGnant as well. 
Moreover, the social networks of participants are used to 
enroll new participants. Pregnant women often know other 
pregnant women. After completion of a questionnaire, the 
participant is asked to send an invitation for the register to 
other pregnant women she knows, thereby increasing the 
number of participants without the intervention of HCPs.
Participants that use antiepileptic medication are asked 
permission to share their data with EURAP (European Reg-
istry of Antiepileptic Drugs and Pregnancy) and receive 
additional questions regarding their disease (e.g., occurrence 
of insults). EURAP is an international study on the risk of 
antiepileptic drug use during pregnancy [35]. In this col-
laboration, data for large numbers of women that use antie-
pileptic drugs during pregnancy are collected in a central 
database. The Dutch data collection for EURAP is embed-
ded in pREGnant. To reach pregnant women with epilepsy, 
additional recruitment methods are employed. The national 
guideline for diagnosis and treatment of epilepsy encourages 
neurologists to discuss the importance of participation in the 
Dutch Pregnancy Drug Register and in that way contribute 
to EURAP as well [36]. Furthermore, recruitment is facili-
tated through promotion on the website of the patient organi-
zation for people with epilepsy and by publications in their 
magazine [37]. pREGnant is also promoted on certain web-
sites of patient organizations of common chronic diseases 
in women of childbearing age, such as ulcerative colitis, 
Crohn’s disease, and rheumatologic diseases. On the website 
of the Royal Dutch Pharmacists Association (KNMP) with 
medication information for the general public, the register 
is mentioned in the section about pregnancy and lactation 
of every medication [38]. The recruitment methods making 
use of an information leaflet or publicity on a website require 
that the woman sign up on the pREGnant website herself.
2.2.1  Effectiveness of Recruitment Methods
The majority of the current participants (64%) were enrolled 
through a digital invitation they received from their HCP. 
The 36% of participants that signed up on the pREGnant 
website were informed about pREGnant through oral or 
written information from their HCP (76%), visiting a website 
on which pREGnant is promoted (11%), a digital invitation 
from another participant (4%), previous participation (3%), 
or otherwise (6%). Because of the different recruitment 
methods, the total number of pregnant women approached 
is unknown, so it is not possible to calculate the exact par-
ticipation rate. In the pilot phase, however, the participation 
rates of some recruitment methods were assessed, being 33% 
when HCPs sent a digital invitation, 16% when a digital 
invitation was sent by another participant, and 6% when the 
information leaflet was handed out or was displayed in the 
waiting area only [data not shown].
2.3  Data Collection: Schedule
The pREGnant, the Dutch Pregnancy Drug Register, started 
on April 1, 2014. Participants receive six web-based ques-
tionnaires in total, except for those who start participation 
after gestational week 20 (see below). Actual participation 
is preceded by completing an online informed consent form, 
in which consent is also asked for linkage of the question-
naire data to data from Perined, the perinatal registry of 
the Netherlands [39], obstetric and medical records, and/or 
pharmacy records. Participants receive a questionnaire at 
enrollment, in gestational week 17, in gestational week 34, 
and 2, 6, and 12 months after the expected date of delivery. 
When a questionnaire is due to be completed, the participant 
automatically receives an invitation by email. If she does 
not act on this invitation or does not fill out the question-
naire completely, a maximum of two reminders will be sent 
(with 6- and 12-day intervals for the questionnaires during 
and after pregnancy, respectively). Participation will auto-
matically end when the questionnaire due is not completed 
within 30 days after the last reminder was sent, resulting 
in loss to follow-up of the participant. This means that it 
is not possible to skip a questionnaire, as this would result 
in missing data on relevant topics. The second question-
naire is the only exception to this rule, as it will be skipped 
in case of enrollment after gestational week 20 and does 
not gather data on topics that are not covered in the other 
questionnaires.
When a miscarriage, elective termination, or stillbirth is 
reported, the questionnaire is adjusted accordingly to obtain 
just a minimal set of data and participation is ended auto-
matically. HCPs or participants may also notify the pREG-
nant team about adverse outcomes by email. In that case, 
participation is ended manually, the reason for attrition is 
documented, and no further questionnaires are sent. When 
participants are lost to follow-up or when a clinical situation 
needs clarification (e.g., maternal disease or birth defect), 
data can be supplemented with data from other sources. Of 
all participants who completed the consent form and the first 
questionnaire, 88.2%, 71.7%, and 68.3% gave permission to 
obtain additional data from Perined, the perinatal registry 
of the Netherlands [39], from obstetric and medical records, 
and from pharmacy records, respectively.
2.3.1  Number of Participants and Follow‑Up Rates
Figure 1 shows the number of invitations sent per question-
naire as well as the number of participants that completed 
the particular questionnaires by March 31, 2018. Because 
of the long period of time in which women are asked to 
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complete questionnaires (from beginning of pregnancy until 
the infant is 1 year of age), many participants are still pend-
ing. Loss to follow-up ranged from 7.4 to 13.9% per ques-
tionnaire. This may be due to a change of email-address, no 
interest in participating any longer, self-initiated withdrawal 
because of an adverse outcome, or other reasons.
2.4  Data Collection: Content
Table 1 provides an overview of the different topics on 
which information is being collected in pREGnant. In all 
questionnaires that concern the pregnancy or breastfeeding 
period, data on maternal health, medication use, and other 
potential determinants of adverse outcomes are collected. In 
case of multiple answer options, checkbox lists are shown, 
always with the possibility of entering additional informa-
tion in a free-text field. When possible, information already 
provided in a previous questionnaire is shown and partici-
pants are asked to verify if the information is still accurate 
or needs elaboration.
Since the outcome measures of interest are, among oth-
ers, pregnancy outcome (miscarriage, elective termination, 
stillbirth, or live birth), birth defects, gestational age, birth 
weight, and effects of medication use during breastfeeding, 
information on these topics is collected as well.
Questionnaire 1 (at enrolment)
# invitations sent: 3672
# questionnaires completed: 3401 (92.6%)
Information leaflet 
Questionnaire 2 (gestational week 17)
# invitations sent: 3080
# questionnaires completed: 2791 (90.6%)
Questionnaire 3 (gestational week 34)
# invitations sent: 2794
# questionnaires completed: 2575 (92.2%)
Questionnaire 4 (2 months after expected due date)
# invitations sent: 2424
# questionnaires completed: 2121 (87.5%)
Questionnaire 5 (6 months after expected due date)
# invitations sent: 1920
# questionnaires completed: 1653 (86.1%)
Questionnaire 6 (12 months after expected due date)
# invitations sent: 1300
# questionnaires completed: 1158 (89.1%)
Registration + informed consent
General advertising 
Email-invitation by HCP
Fig. 1  Scheme depicting recruitment and follow-up in the pREGnant, the Dutch Pregnancy Drug Register. Status as of March 31, 2018. HCP 
healthcare provider
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Medication use is asked about in an indication-oriented 
manner to enhance maternal recall [40, 41]. Participants first 
select relevant indications from predefined lists, which is fol-
lowed by showing specific medication names for the selected 
indication(s). Based on the medication name that is chosen, 
tailored multiple-choice questions about formulation, dos-
age, and period of use are shown. When a participant used 
a medication that is not shown (e.g., off-label use), they can 
provide the medication name and the subsequent informa-
tion on formulation, dosage, and period of use as open text. 
In this way, prescribed, over-the-counter medications, and 
non-registered medications can be reported.
3  Characteristics of Participants
Table 2 shows the general characteristics of the participants 
included in the pREGnant, the Dutch Pregnancy Drug Regis-
ter, from April 1, 2014 through March 31, 2018. At that time, 
3401 pregnant women were enrolled and had completed at 
least the first questionnaire. The characteristics of the par-
ticipants at baseline were compared with those of women 
that gave birth in 2015 or with women of childbearing age in 
the Netherlands in 2016 [42–44]. Participants in pREGnant 
were more often highly educated and had a higher maternal 
age at the expected date of birth than the entire Dutch preg-
nant population. Maternal country of birth differed as well, 
as participants were more often born in the Netherlands. In 
the first questionnaire, 63.5% of the participants reported 
the use of at least one medication during their pregnancy 
up to completion of the questionnaire (median: gestational 
week 10.7). Of these women, 1167 (54.0%) reported the 
use of more than one type of medication. Table 3 shows the 
individual medication names that were reported by at least 
2% of the participants in the first questionnaire. Of the 12 
most commonly reported medications, seven were available 
over the counter, with acetaminophen use being reported by 
21.1% of the pregnant women.
4  Establishment of the Design
The design of the Dutch Pregnancy Drug Register was 
established during a pilot phase, in which it was evaluated, 
optimized, and organized in a sustainable way to ensure 
ongoing enrollment and good quality data collection. Based 
on feedback from participants and HCPs, the content and 
clarity of the questionnaires are being evaluated at regular 
intervals. Initially, the PRegnancy and Infant DEvelopment 
(PRIDE) study, coordinated by the Radboud university 
medical center [45], served as a template for the pREGnant, 
the Dutch Pregnancy Drug Register, as it has a comparable 
web-based approach to obtaining information on a broad Ta
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Table 2  Characteristics of women enrolled in the pREGnant, the Dutch Pregnancy Drug Register, from April 1, 2014 through March 31, 2018 
compared with Dutch women who gave birth in 2015 or Dutch women of childbearing age in 2016
BMI body mass index
a Maternal age at expected due date
b Data retrieved from Perined, the perinatal registry of the Netherlands regarding perinatal care, report 2015 (pregnant women) (17)
c Data from the Centre for Policy-related Statistics (CBS), 2016, women aged 25–35 years (not pregnant) (18)
d Data from the Centre for Policy-related Statistics (CBS), 2016, women aged 30–40 years (not pregnant) (19)
Participants in pREGnant (N = 3401) General population of 
Dutch women
N % %
Maternal  agea
 18–19 years 1 0.0 1.0b
 20–24 years 129 3.8 9.3b
 25–29 years 913 26.8 30.9b
 30–34 years 1617 47.5 38.1b
 35–39 years 666 19.6 17.6b
 ≥40 years 74 2.2 3.2b
 Unknown 1 0.0
Maternal country of birth
 The Netherlands 3218 94.6 74.0b
 Other 170 5.0 26.0b
 Missing 13 0.4
Maternal level of education
 Low 99 2.9 11.7c
 Intermediate 919 27.0 37.4c
 High 2370 69.7 49.4c
 Unclassifiable 3 0.1
 Missing 10 0.3
Pre-pregnancy BMI
 ≤24.9 kg/m2 2182 64.2 60.4d
 >25.0 820 24.1 39.6d
 Missing 399 11.7
Parity
 Primiparae 1760 51.7 44.6b
 Multiparae 1638 48.2 55.4b
 Missing 3 0.1
Fertility treatment
 Yes 275 8.1 4.7b
 No 3124 91.9 67.4b
 Missing 2 0.1 27.8b
Plurality (N = 2911)
 Singleton 2819 96.8 98.3b
 Multiple 36 1.2 1.7b
 Unknown 2 0.1
 Missing 54 1.9
Permission linkage with perined 3001 88.2
Permission review medical/obstetric records 2440 71.7 98.3b
Permission review pharmacy records 2324 68.3 1.7b
Median Q1–Q3
Gestational week at enrollment 10.7 8.9–13.3
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range of potential risk factors, including medication use, and 
pregnancy and offspring outcomes. However, the PRIDE 
study has broader objectives and a longer follow-up period, 
and recruitment of participants will end in due time. Within 
the framework of the grant to establish the Dutch Pregnancy 
Drug register, several validation studies were performed to 
assess the merits of the methodology and the quality of the 
data collection [46–48]. Because pREGnant required a sub-
stantial period of preparatory work before actual recruit-
ment of participants, these validation studies were mainly 
performed within the PRIDE study, but the results are appli-
cable to pREGnant as well.
4.1  Data Validation
One of the validation studies showed that web-based ques-
tionnaires completed by pregnant women seem to be a valid 
method to obtain data on chronic disorders and allergies 
with equal or better data quality compared with obstetric 
records [46]. Another validation study showed that perinatal 
outcomes, such as gestational age and birth weight, were 
reported well in the web-based maternal questionnaires and 
showed only minor discrepancies with obstetric records [47]. 
The web-based data collection on medication exposure dur-
ing pregnancy was validated by comparing the web-based 
questionnaires of both pREGnant and the PRIDE study with 
paper-based medication diaries that were completed by the 
participants over a period of 6 weeks as reference standard. 
The degree of under-reporting in the web-based question-
naires was limited for a large number of medication groups 
used for chronic or pregnancy-related conditions. Medica-
tions for occasional and short-term use were under-reported 
more frequently. However, the sensitivity of most medica-
tions in the web-based questionnaires with indication-
directed questions was higher compared with paper-based 
data collection efforts [48]. In addition, detailed informa-
tion on medication use is obtained through the web-based 
questionnaires, including data on indication for use, dose, 
formulation, and moment or period of exposure.
5  Strengths and Limitations of the Design
The main strengths of the Dutch Pregnancy Drug Register 
are the nature and quality of the data. The web-based data 
collection has several advantages over paper-based data col-
lection: data entry errors are limited by the use of validation 
rules on data fields, and the willingness to report sensitive 
information may be increased [49, 50]. User friendliness 
is high, as questions are shown conditionally on former 
answers, and a subset of previously reported information is 
transferred to the next questionnaire.
Exposure data cover prescribed medication as well as 
over-the-counter medication and non-registered medications. 
For medication available without prescription, even fewer 
studies are available regarding use during pregnancy [25, 
51–53]. As the woman herself is the main source of data, 
detailed information on the use of all kinds of medication is 
reported, and data on actual use (i.e., compliance) and exact 
timing of medication use are obtained as well. In pREGnant, 
maternal recall is enhanced by indication-oriented questions 
as recommended in previous studies [40]. As shown in our 
validation study, pregnant women report their medication 
use reliably for most medication groups [48], which is 
important when studying associations between medication 
exposure during pregnancy and potential adverse outcomes.
The design allows for different outcome parameters to be 
studied. Besides birth defects, other study outcomes of inter-
est include birth weight and gestational age at birth, which 
were found to be of good quality [47]. Follow-up until the 
infant is 1 year of age allows for a more complete registra-
tion of the total number of birth defects compared with the 
short-term follow-up available in obstetric records and most 
birth registries [54, 55]. Estimates from EUROCAT North-
Netherlands showed that up to 95% of birth defects were 
diagnosed within the first year (de Walle H, personal com-
munication). Concomitantly, the follow-up period of pREG-
nant offers the opportunity to get more insight into deci-
sions made concerning breastfeeding and medication use, 
as well as into the occurrence of adverse effects in the infant 
related to maternal medication use in this period. Currently, 
Table 3  Individual medication names for which use during preg-
nancy was reported in the first questionnaire by at least 2% of the par-
ticipants
a Over-the-counter medication
b The Dutch data collection for European Registry of Antiepileptic 
Drugs and Pregnancy (EURAP), an international registry of antiepi-
leptic drugs and pregnancy, is embedded in pREGnant (35)
c Over-the-counter as well as prescribed medication
Medication name Participants
N (%)
Acetaminophena 719 (21.1)
Meclozine/pyridoxine 197 (5.8)
Xylometazolinea 154 (4.5)
Lamotrigineb 152 (4.5)
Calciumcarbonate/magnesiumcarbonate 
 (Rennie®)a
136 (4.0)
Levothyroxine 116 (3.4)
Levetiracetamb 100 (2.9)
Salbutamol 88 (2.6)
Cetirizinea 72 (2.1)
Macrogol (and combination products)a 70 (2.1)
Omeprazolec 69 (2.0)
Aciclovira 68 (2.0)
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long-term outcomes, such as developmental milestones and 
neurodevelopmental disorders, are not part of pREGnant.
Despite the importance of including data on potential 
confounding factors in epidemiologic analyses, this infor-
mation is lacking in various studies [56–61]. pREGnant 
has the advantage that data on a wide range of potential 
confounding factors are collected directly from the partici-
pants. Information is obtained on lifestyle factors, including 
smoking habits, use of alcohol, illicit drug use, and intake of 
folic acid and other food supplements, as well as on chronic 
conditions, pregnancy complications, and the indications for 
medication use. Furthermore, information on demographics, 
such as maternal age, educational level, and country of birth 
are obtained.
The pREGnant, the Dutch Pregnancy Drug Register, 
targets the entire Dutch pregnant population. The pREG-
nant cohort consists of women with and without specific 
medication use or diseases and allows the selection of suit-
able reference groups for different research questions. Cur-
rently, the participants form only a small percentage of the 
target population, and representativeness for the general 
pregnant population in the Netherlands is limited (Table 2). 
Initiatives are taken to increase the coverage (see future 
directions in Sect. 7), but selective participation cannot be 
prevented completely. The influence of selective participa-
tion will most likely be reflected in the maternal variables 
[62–65]. Selective loss to follow-up may, for instance, occur 
when women with an adverse outcome may be more prone 
to drop out or could be more motivated to report this out-
come. Alternatively, women who face dilemmas concerning 
medication use during pregnancy or breastfeeding might be 
more motivated to start and/or keep participating [66, 67]. 
However, selective participation is not expected to have 
large effects on exposure–outcome associations directly, 
and potential confounding factors that may differ between 
pREGnant participants and the general population can be 
included in the analyses. Currently, we have no insight into 
whether the outcome measures of the women remaining in 
the register differ from the ones that are lost to follow-up. 
However, the missing data from participants that were lost to 
follow-up may partially be supplemented by retrieving data 
from other sources. If a woman gave permission, data on the 
pregnancy and outcome can be obtained from Perined and 
obstetric or medical records, and data on prescribed medica-
tion can be obtained from pharmacy records. A limitation of 
the pREGnant design is under-representation in pregnancies 
that end in an early miscarriage, resulting from enrollment 
of participants throughout pregnancy.
The Dutch Pregnancy Drug Register will not only provide 
data on potential adverse effects associated with medication 
use during pregnancy and breastfeeding, but will also provide 
data that support rational use. The approach ensures frequent 
reporting of commonly used medication among pregnant and 
breastfeeding women. The knowledge on the benefits and 
potential risks for maternal and fetal/infant health that will be 
obtained will therefore be relevant for public health. Since lim-
ited numbers of pregnancies are exposed to rarely used medi-
cations and specific birth defects occur at low frequency, one 
of the weaknesses of the register is the relative low number of 
participants at this time, which gives rise to a lack of statistical 
power to perform association studies on these medications and 
outcomes. This stresses the importance of large-scale imple-
mentation in the Netherlands and international collaboration 
[68].
6  Applicability of the Data from the Register
The data in the Dutch Pregnancy Drug Register provide an 
excellent opportunity to perform exposure–outcome associa-
tion studies for commonly used medications during preg-
nancy and breastfeeding. Also, the data will be evaluated 
periodically to screen for potential adverse events resulting 
from medication use during pregnancy or breastfeeding. 
Proper risk assessment regarding medication use during 
pregnancy and breastfeeding is often complicated by the 
lack of evidence-based data. The well documented cases in 
pREGnant offer a way to support the counseling of HCPs 
by the Dutch TIS, thereby allowing more rational use of 
medication during pregnancy and breastfeeding [69].
7  Future Directions
The pREGnant, the Dutch Pregnancy Drug Register, was 
developed, validated, and evaluated in recent years. Cur-
rently, steps are being taken to implement pREGnant on a 
large scale in the Netherlands. As enrollment of pregnant 
women is most efficient when HCPs actively invite them 
for participation, this requires some additional effort by the 
HCP. The current approach may not be feasible in the long 
run. Therefore, with input from our advisory committee 
consisting of experts in the field of prenatal care, efforts are 
being made to integrate sending of the digital invitation for 
pREGnant into the midwives’ digital practice information 
systems, thereby embedding pREGnant within the routine 
of prenatal care in the Netherlands.
At the moment, the indication for medication use is 
reported. As the severity of maternal disease is an impor-
tant confounding factor for several outcome parameters, the 
possibility to document disease severity accurately will be 
explored. Data on long-term outcomes, such as developmen-
tal milestones and neurodevelopmental disorders, may be 
added to the data collection of pREGnant in the future as 
well.
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8  Collaboration
Researchers interested in collaboration, using the infrastruc-
ture, or performing a study with data from pREGnant are 
welcome to contact the principal investigator (info@preg-
nant.nl). For further questions or more information, please 
contact us through this email address as well.
The current dataset may already contain all data required 
to answer certain research questions. The flexibility within 
the IT application, however, also facilitates the inclusion 
of tailor-made questions for a specific subpopulation, or 
extensions of the data collection for a limited period of time. 
Therefore, if additional information is desired, data collec-
tion may be extended temporarily or data could be obtained 
through linkage with other sources. For applications, we 
request a short proposal including background information, 
a clearly defined research question, a plan for analysis, a 
time schedule, and a publication plan. The scientific advi-
sory board of pREGnant will review the proposal. When 
approved, the mutual agreements will be formalized in a 
contract.
9  Conclusion
The pREGnant register is well established and validated. 
The current focus is increasing the number of participants 
by implementing the register on large scale.
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